undamentalytics Newsletter
Sign in

Harmony Biosciences Holdings, Inc. balance sheet

At the end of fiscal 2025, Harmony Biosciences Holdings, Inc. had total assets of $1.27bn, total liabilities of $401m and shareholders' equity of $870m. It held $753m in cash against $165m of debt: net cash of $588m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents24229234244312453753550
Receivables4223555748397111
Inventory14445756
Total current assets31263284400451579907814
Total assets1074274336748119991,2721,373
Accounts payable631418141822
Total current liabilities201355479164175252234
Short-term debt——2215162020
Long-term debt98194190190179163144134
Total debt98200200198196181165155
Total liabilities118330247271344340401374
Shareholders' equity−42397187403467659870999
Non-controlling interests and other (assets − liabilities − equity)411———————
Net debt (negative = net cash)73−29−35−46−115−272−588−395
Shares outstanding8m—59m60m57m57m58m58m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ANIP vs HRMYAXSM vs HRMYHRMY vs SUPNHRMY vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Harmony Biosciences Holdings, Inc.